SHANGHAI and BOSTON, April 17, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate (ADC), today announced its second...
Hence then, the article about velavigo announces second out licensing deal of a first in class bi specific antibody further validating its innovative discovery platform and sustainable bd vc business model was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model )
Also on site :
- Clarks’ ‘Comfortable’ Loafers Have Shoppers Walking ‘All Day With No Fatigue,’ and They’re on Sale for $60
- 1968 Song by The Rolling Stones, Ranked Among ‘Greatest Protest Rock Songs,’ Is Still a Powerful Hit 58 Years Later
- We Asked 3 Disney Travel Experts for the Best Multigenerational Family Vacation Upgrade—They All Said the Same Thing